Exhibit R-2, RDT&E Budget Item Justification: PB 2014 Navy

APPROPRIATION/BUDGET ACTIVITY

R-1 ITEM NOMENCLATURE

1319: Research, Development, Test & Evaluation, Navy

PE 0604771N: Medical Development

BA 5: System Development & Demonstration (SDD)

COST (\$ in Millions)	All Prior Years	FY 2012	FY 2013 [#]	FY 2014 Base	FY 2014 OCO ##	FY 2014 Total	FY 2015	FY 2016	FY 2017	FY 2018	Cost To Complete	Total Cost
Total Program Element	25.948	32.118	14.880	9.458	-	9.458	9.643	10.225	10.394	10.011	Continuing	Continuing
0933: Medical/Dental Equipment Dev	9.234	14.018	14.880	9.458	-	9.458	9.643	10.225	10.394	10.011	Continuing	Continuing
9999: Congressional Adds	16.714	18.100	0.000	0.000	-	0.000	0.000	0.000	0.000	0.000	0.000	34.814

[#] FY 2013 Program is from the FY 2013 President's Budget, submitted February 2012

A. Mission Description and Budget Item Justification

The purpose of this budget item is to develop biomedical equipment and related techniques to reduce morbidity; to enhance the logistic feasibility of modern medical care for combat casualties; to sustain casualties for evacuation to fixed medical facilities for definitive care; and to ensure that personnel are medically qualified for military duty. There is a strong potential for dual use, technology transfer, and biotechnology firms/industry participation in the projects.

B. Program Change Summary (\$ in Millions)	FY 2012	FY 2013	FY 2014 Base	FY 2014 OCO	FY 2014 Total
Previous President's Budget	33.034	12.707	9.471	-	9.471
Current President's Budget	32.118	14.880	9.458	-	9.458
Total Adjustments	-0.916	2.173	-0.013	-	-0.013
 Congressional General Reductions 	-	-			
 Congressional Directed Reductions 	-	-			
 Congressional Rescissions 	-	-			
 Congressional Adds 	-	-			
 Congressional Directed Transfers 	-	-			
Reprogrammings	-0.041	0.000			
SBIR/STTR Transfer	-0.875	0.000			
Rate/Misc Adjustments	0.000	2.173	-0.013	-	-0.013

Congressional Add Details (\$ in Millions, and Includes General Reductions)

Project: 9999: Congressional Adds

Congressional Add: Military Dental Research

Congressional Add: Wound Care Research (transferred from Defense Health Program)

FY 2012	FY 2013			
5.100	_			
13.000	-			
18.100	0.000			

Congressional Add Subtotals for Project: 9999

^{##} The FY 2014 OCO Request will be submitted at a later date

<u> </u>				: April 2013	
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: System Development & Demonstration (SDD)		MENCLATURE : Medical Development			
Congressional Add Details (\$ in Millions, and Includes Ge	eneral Reductions)			FY 2012	FY 2013
		Congressional Add Totals for all P	rojects	18.100	0.000

PE 0604771N: Medical Development

UNCLASSIFIED Page 2 of 22

Exhibit R-2A, RDT&E Project	Exhibit R-2A, RDT&E Project Justification: PB 2014 Navy								DATE: April 2013			
APPROPRIATION/BUDGET A 1319: Research, Development BA 5: System Development & I	Test & Evaluati	•			R-1 ITEM I PE 060477		 nent	PROJECT 0933: Med		Equipment l	Dev	
COST (\$ in Millions)	All Prior			FY 2014	FY 2014	FY 2014				Cost To	Total	

COST (\$ in Millions)	All Prior Years	FY 2012	FY 2013 [#]	FY 2014 Base	FY 2014 OCO ##	FY 2014 Total	FY 2015	FY 2016	FY 2017	FY 2018	Cost To Complete	Total Cost
0933: Medical/Dental Equipment Dev	9.234	14.018	14.880	9.458	-	9.458	9.643	10.225	10.394	10.011	Continuing	Continuing
Quantity of RDT&E Articles	0	0	0	0		0	0	0	0	0		

^{*}FY 2013 Program is from the FY 2013 President's Budget, submitted February 2012

A. Mission Description and Budget Item Justification

The purpose of this budget item is to develop biomedical equipment and related techniques to reduce morbidity; to enhance the logistic feasibility of modern medical care for combat casualties; to sustain casualties for evacuation to fixed medical facilities for definitive care; and to ensure that personnel are medically qualified for military duty. Each work unit undertaken in this project has a military requirement. Efforts are justified based upon military payoff and cost benefit. There is a strong potential for dual use, technology transfer, and biotechnology firms/industry participation in the projects.

B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)	FY 2012	FY 2013	FY 2014
Title: Medical/Dental Equipment Dev	12.068	12.707	9.458
Articles:	0	0	0
FY 2012 Accomplishments:			
Wound Management Program - Integrate efforts in wound closure, Hyperspectral Imaging, Heterotopic Ossification, and stem cell applications for wound repair. The system will provide improved diagnostic measures of wound healing.			
Monitoring, Oxygen Ventilation and External Suction (MOVES) System -Continued effort toward providing enhance capability for enhance control module & cardiovascular monitoring.			
Intranasal Carbon Dioxide for Headache and Trigeminal Muscle Pain - Continued efforts to provide an abortive migraine therapy with minimal side effects and high efficacy for use on deployment and in Military Treatment Facilities. Lead study data integrator identified to coordinate research sites.			
Attenuated Sporozoite Malaria Vaccine for Military Personnel - Continued augmented efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising novel vaccine candidate.			
Impact of Marine Suicide on Family Survivors - Penn State will examine factors predicting resilience and well-being of Marine Corps families and determine needs addressable by intervention techniques.			

^{##} The FY 2014 OCO Request will be submitted at a later date

Exhibit R-2A, RDT&E Project Justification: PB 2014 Navy		DA	E: April 2013		
APPROPRIATION/BUDGET ACTIVITY	R-1 ITEM NOMENCLATURE	PROJECT			
1319: Research, Development, Test & Evaluation, Navy	PE 0604771N: Medical Development	0933: Medical/l	0933: Medical/Dental Equipment Dev		
BA 5: System Development & Demonstration (SDD)					
B. Accomplishments/Planned Programs (\$ in Millions, Article Q	· · · · · · · · · · · · · · · · · · ·	FY 201	2 FY 2013	FY 2014	
USMC Suicide Prevention Program Resiliency Study and Related E study, adding targeted studies of Marines that may be applicable to assessments to include 12-month after deployment return to determ Effort includes assessment of postvention efforts and psychological	larger cohorts. Proposed aims include addition of nine risk for chronic PTSD and potential factors for mitig				
Implementation of an Alternative Watchstanding Schedule on Navy fatigue-mitigated scheduling.	Surface Combatants - Initiate study to analyze individu	ualized			
Human Factors Support of OWL Tool - initiate development of syste order to: coordinate fleet user survey; perform task analysis; assist (submit IRB protocols; and generate technical reports.	• ''	-			
Intranasal Scopolamine - Initiate study for the prevention of motion s	sickness in dynamic military environments.				
Battalion Aid Station (BAS) Capabilities Study - Initiate study to cond by Marine Ground Combat Element (GCE) during garrison, continge (ACE)					
Clinical Trials Site Expansion for Biomarkers - Biomarker study and Program.	clinical trials site expansion in support of Wound Mana	gement			
Treatment Response Modeling for Crew Injuries Resulting from Weath chain requirements for evacuation patient outcomes. Determined put with software developer to ensure interoperability with the Office of N	robabilistic representation of mortality function and coo	ical rdinated			
SUBSCREEN Modification - The submarine duty psychological scre for mixed gender use; this modification study will execute these fund		alidation			
Biosurveillance Information Service (BioServ) - Develop a Biosurveil multiple data sets related to current and projected health risks enhance levels.					
Rapid Blood Typing for Role II Units with Naval Medical Research U typing industry standard against proposed kit.	Init - San Antonio (NAMRU-SA) - Compare automated	blood			

Exhibit R-2A, RDT&E Project Justification: PB 2014 Navy			DATE:	April 2013	
APPROPRIATION/BUDGET ACTIVITY	R-1 ITEM NOMENCLATURE	PROJ	ECT		
1319: Research, Development, Test & Evaluation, Navy	PE 0604771N: Medical Development	0933:	0933: Medical/Dental Equipment Dev		
BA 5: System Development & Demonstration (SDD)					
B. Accomplishments/Planned Programs (\$ in Millions, Article Qua	antities in Each)		FY 2012	FY 2013	FY 2014
Validation of Computerized Color Vision Tests for Use in Naval Aviation instruments developed to detect and diagnose color vision deficiencie that may compromise safety and operational performance in next gen	s for potential use to screen candidates for color defi	ciencies			
Sterilucent Sterilizer - develop a portable, efficient sterilizer that opera process and a fast turn around time. Done in conjunction with MARCO		ıre			
Noise-Induced Hearing Loss: Administration of NAC and HPN-07-Clin by completing the toxicology, pharmacokinetic and animal efficacy and		-1010			
Synthetic Platelets in Swine Liver Injury Model - Develop an intraveno survival following a liver injury in swine.	ous infusible nanoparticle product to promote hemost	asis and			
Clinical Trials Site Expansion for Biomarkers - Biomarker study and cl Program.	linical trials site expansion in support of Wound Mana	gement			
Individualized Fatigue-Based Scheduling and Countermeasure Syster predicts, prevents, detects, and mitigates periods of high risk associate funded by the Office of Naval Research.					
FY 2013 Plans: Mobile Oxygen Ventilation and External Suction (MOVES) Anesthesia anesthesia module. This device is a pre-planned product improvement Corpsman, and Navy or USMC Special Operations. Joint effort to res	nt for FRSS deployment for MTFs, Medicine Clinics,	S			
Wound Management Program - Continued integration efforts in wound and stem cell applications for wound repair. The system will provide in		cation,			
SUBSCREEN Modification - This study will be completed and result ir for mixed gender use.	n the required modification and validation of SUBSCF	REEN			
Intranasal Carbon Dioxide for Headache and Trigeminal Muscle Pain migraine therapy with minimal side effects and high efficacy for use or					

PE 0604771N: Medical Development

Navy

Page 5 of 22 R-1 Line #125

	UNULAGGII ILD					
Exhibit R-2A, RDT&E Project Justification: PB 2014 Navy		,	DATE:	April 2013		
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: System Development & Demonstration (SDD)	R-1 ITEM NOMENCLATURE PE 0604771N: Medical Development		ROJECT 33: Medical/Dental Equipment Dev			
B. Accomplishments/Planned Programs (\$ in Millions, Article Qu	uantities in Each)		FY 2012	FY 2013	FY 2014	
Individualized Fatigue-Based Scheduling and Countermeasure Syste that predicts, prevents, detects, and mitigates periods of high risk ass Research to facilitate transition.						
USMC Suicide Prevention Program Resiliency Study and Related Eff study and the execution of targeted studies of Marines. Address aim after deployment return to determine risk for chronic PTSD and poter postvention efforts and psychological studies.	ns including addition of assessments to include 12-mo	nth				
Joint Development Projects with MARCORSYSCOM Medical Acquis program for medical products and equipment. Finalize development	ation					
Transition Projects from Force Health Protection Future Capability - 0 transition products from the Office of Naval Research 6.3 Advanced I hemostatic agents (e.g. infusible hemostatics and field/first responde	Development program. Focus will be on transition of					
Attenuated Sporozoite Malaria Vaccine for Military Personnel - Comptest, for safety and efficacy, a militarily relevant malaria vaccine regin		effort to				
Individualized Fatigue-Based Scheduling and Countermeasure System predicts, prevents, detects, and mitigates periods of high risk associatisk will be predicted and prevented by providing individual, specific, and prevented by providing individual.	ated with fatigue. Periods of high individualized perfor	mance				
USMC Suicide Prevention Program Resiliency Study and Related Eff study and the execution of targeted studies of Marines. Address aim after deployment return to determine risk for chronic PTSD and poter postvention efforts and psychological studies.	ns including addition of assessments to include 12-mo	nth				
Biosurveillance Information Service (BioServ) - Define decision rules notifications.	for data sources to allow for dissemination of warning	9				
Rapid Blood Typing for Role II Units with Naval Medical Research Ur reliable, and user-friendly field use.	nit - San Antonio (NAMRU-SA) - Test proposed kit fo	rapid,				

PE 0604771N: Medical Development

Navy

Page 6 of 22 R-1 Line #125

Exhibit R-2A, RDT&E Project Justification: PB 2014 Navy		DA	TE: A	pril 2013		
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: System Development & Demonstration (SDD)	R-1 ITEM NOMENCLATURE PE 0604771N: Medical Development	PROJECT 0933: Medical	PROJECT 0933: Medical/Dental Equipment Dev			
B. Accomplishments/Planned Programs (\$ in Millions, Article Q	uantities in Each)	FY 20	12	FY 2013	FY 2014	
Validation of Computerized Color Vision Tests for Use in Naval Avia parameters are met.	tion - Conduct a validation study to ensure key perform	ance				
Foreign Directed Energy System Exploitation - Exploitation of foreig	n directed energy devices for bioeffects.					
FY 2014 Plans: USMC Suicide Prevention Program Resiliency Study and Related Estudy and the execution of targeted studies of Marines.	fforts - Complete research leveraging the Marine Resilie	ency				
Attenuated Sporozoite Malaria Vaccine for Military Personnel - Contia militarily relevant malaria vaccine regimen utilizing a promising nov	icacy,					
Biosurveillance Information Service (BioServ) - Conduct training and	d develop maintenance plan.					
Rapid Blood Typing for Role II Units with Naval Medical Research U Laboratory Improvement Amendment waiver and Biologica License manufacturing processes.		on on				
Validation of Computerized Color Vision Tests for Use in Naval Avia diagnostic error rate (less than the current 20% of color deficient car		lower				
Transition Projects from Force Health Protection Future Capability - for transition products from the Office of Naval Research 6.3 Advance resuscitation agents, and mitigation of neurotrauma and post-trauma	ced Development program. Focus will be on transition of					
Title: Tactical Logistics Planning Tool	A	orticles:	.475	0.481 0	0.000	
FY 2012 Accomplishments: OCO: Discovery phase to identify the information technology structures an wargaming simulations has commenced. Implementation, testing, a						
FY 2013 Plans: OCO:						

PE 0604771N: Medical Development

Navy

UNCLASSIFIED Page 7 of 22

Exhibit R-2A, RDT&E Project Justification: PB 2014 Navy			DATE: /	April 2013	
APPROPRIATION/BUDGET ACTIVITY	R-1 ITEM NOMENCLATURE	PROJ	ECT		
1319: Research, Development, Test & Evaluation, Navy	PE 0604771N: Medical Development	0933:	933: Medical/Dental Equipment Dev		
BA 5: System Development & Demonstration (SDD)					
B. Accomplishments/Planned Programs (\$ in Millions, Article Qu	•		FY 2012	FY 2013	FY 2014
A research tool that models patient flow from the point of injury through operational risk assessment, field medical services planning and system. TML+ provides the capability to model medical treatment facilities at number and type of personnel, and the type, speed, and capacity of specific modeling capabilities in TML+ to support the development of combat casualties using the minimum amount of manpower, materie	tems analysis. Because it can handle larger amounts all levels of care and their respective functional areas, transportation assets. The plan is to continue to devel OCO medical plans that optimize clinical outcomes for	of data, the op			
Title: Combat Trauma Registry - Expeditionary Medical Encounter D		rticles:	0.875 0	0.892 0	0.000
FY 2012 Accomplishments: OCO: Commenced development of a tri-service expeditionary database that injury, disease, and mental health encounters) to create a continuous		attle			
FY 2013 Plans: OCO: Tri-service database of all battle injuries, non-battle injuries, disease, treatment facilities supporting OCO. The CTR EMED tracks each ca injuries and severities in near real-time. The tactical, operational, an materiel developer and threat mitigation communities. Continue to method the ocontinue to method the ocontinu	sualty, develops a detailed injury profile of the casualt d casualty clinical data are forwarded to the intelligence	y's e,			
Title: Validation of the Human Surrogate (HS) Prototype	A	rticles:	0.240	0.400	0.000
FY 2012 Accomplishments: OCO: Began pre-testing of human surrogate equipment for biofidelic experi	imental response.				
FY 2013 Plans: OCO: Validation of the Human Surrogate (HS) Prototype will help determine Explosive Devices (IEDs) devices and munitions. The HS model, de to make accurate measurements of the specific absorption rate (SAF Controlled Electronic Warfare (CREW) devices. The absorption of rais well known that even uniform RF exposures lead to non-uniform all	eveloped by Greenwave Scientific Inc., designed to be R) of RF energy in the human body from Counter Radio adiofrequency (RF) by the human body is very completed.	used o- c. It			

Exhibit R-2A, RDT&E Project Justification: PB 2014 Navy			DATE:	April 2013	
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: System Development & Demonstration (SDD)	R-1 ITEM NOMENCLATURE PE 0604771N: Medical Development	PROJECT 0933: Medi	cal/Den	tal Equipment	t Dev
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities	in Each)	FY	2012	FY 2013	FY 2014
methods to measure SAR in the human body are elegant and elaborate proce laboratory. These consist of open and closed human phantom shells filled wit human tissue. To measure the uneven absorption of RF energy a small electric the phantom shell during exposure.	h liquids that simulate the electrical properties o				
Continue work on the HS model and the evaluation of the accurate measurem energy in the human body from Counter Radio-Controlled Electronic Warfare studies looking at the long term use of the Counter Radio-Controlled Electronic	devices. Start developing some initial research				
Title: Laser Field Testing	Artı	icles:	0.143 0	0.400	0.000
FY 2012 Accomplishments: OCO Initiated Acoustic and Laser Field Test efforts to evaluate commercial-off-the-s weapons technology complete to evaluate the effectiveness of a combined accomplination warning device.		and			
FY 2013 Plans: OCO: Based on a 5th Fleet Urgent Requirement, an evaluation of various commercial (GOTS) Non-Lethal Weapons (NLW) technology is required to determine the edevice as a long range NLW hailing and warning device. The bioeffects effort for these NLW devices and future acquisition to deploy these types of systems. Continue the laboratory and field testing of the effectiveness of a combined Activities and warning devices. Conduct additional field testing under apparational	effectiveness of a combined Acoustic and Laser will support legal, policy and treating developm in theatre. coustic and Laser device as a long range NLW	-			
hailing and warning device. Conduct additional field testing under operational Title: Counter Directed Energy Bio-effects		icles:	0.217	0.000	0.000
FY 2012 Accomplishments: Counter Directed Energy Bio-effects: Test chambers/facilities subjected to cere methodologies for protection.	tification for testing of directed energy effects ar	nd			
	Accomplishments/Planned Programs Subt	otals	14.018	14.880	9.458

DATE: April 2013 Exhibit R-2A, RDT&E Project Justification: PB 2014 Navy APPROPRIATION/BUDGET ACTIVITY **R-1 ITEM NOMENCLATURE PROJECT**

1319: Research, Development, Test & Evaluation, Navy PE 0604771N: Medical Development 0933: Medical/Dental Equipment Dev

BA 5: System Development & Demonstration (SDD)

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

The acquisition strategy for product lines and products in the Medical Development Program is designed and implemented consistent with the particular product and with the nature and size of the investment.

The Medical Development Program operates with a Memorandum of Understanding with the Marine Corps Systems Command (Family of Field Medical Equipment) for co-development of products for procurement by the USMC. The acquisition strategy for these products involved direct partnership with the acquisition and procurement professionals at Marine Corps Systems Command. The program's major Product Areas in the Medical Development Program are: 1) Equipment 2) Pharmaceuticals/ Biologics, and 3) Knowledge/Concepts. The primary Program Areas of Interest are in: 1) Expeditionary Medicine (Navy in Terrestrial, Maritime Surface, Submarine, & Aviation Operations and USMC in Expeditionary Operations) - in these areas the focus is on Levels I and II in Clinical Care Medicine; and 2) Products developed for battlefield treatment of Combat Casualties & Combat Trauma, focusing on delivery of Levels III and IV of care.

For areas 1 and 2, there are two primary acquisition strategies. The first is to test and evaluate commercially-developed medical product candidates in managed trials for ultimate Food and Drug Administration (FDA) approval. Partnerships with commercial developers ensure that products of military interest are available for procurement across the DoD, Federal Government, and commercial market. During development, DoD end users are included in the process to the extent possible. The second strategy is to drive the development process with DoD program investments. This process involves developing in-house or industrial prototypes in government-managed programs to meet military and regulatory reguirements for production and fielding.

Both strategies promote advanced preparation of procurement plans in line with the product availability. Major Medical Development programs falling in these categories are: MOVES and MOVES anesthesia module (Equipment), Dengue vaccine, and Infusible Hemostatic-Phase I Clinical Trials (Pharmaceuticals/Biologics).

The Third Product Area (Knowledge/Concepts) is focused on the introduction of technologies, techniques, and procedures that alter medical practice and standards of care. These primarily require early involvement of the senior leadership of military medicine, in that the result of the program is modification of concepts of operations, policy, and/or doctrine. These are often much smaller; Medical Development Program examples include Navy/USMC Medical Planning Requirement Assessment and Crisis Action Planning Tool Transition.

Programs such as System for Objective Decision-Making on Timing of Wound Closure involve both material and knowledge solutions.

E. Performance Metrics

Maintaining Scheduled Milestones/Demonstration Events for individualized project/product roadmap. Ensuring dependencies across multiple efforts are maintained on schedule and are primary metrics.

UNCLASSIFIED

PE 0604771N: Medical Development

Page 10 of 22

R-1 Line #125

Navy

Exhibit R-3, RDT&E Project Cost Analysis: PB 2014 Navy

R-1 ITEM NOMENCLATURE

DATE: April 2013 **PROJECT**

APPROPRIATION/BUDGET ACTIVITY

1319: Research, Development, Test & Evaluation, Navy BA 5: System Development & Demonstration (SDD)

PE 0604771N: Medical Development

0933: Medical/Dental Equipment Dev

Product Developmen	oduct Development (\$ in Millions)			FY 2	2012	FY 2	2013		2014 ase		2014 CO	FY 2014 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	All Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To	Total Cost	Target Value of Contract
P. Falciparum Malaria Vaccine for Military Personnel	MIPR	NMRC:Silver Spring, MD	0.700	3.774	Jun 2012	1.813	Dec 2012	0.000		-		0.000	0.000	6.287	
Wound Management Program (Hyperspectral Imaging/System for Objective Decision- Making on the Timing of Wound Closure/Hetrotopic Ossification	SS/FP	NMRC:Silver Spring, MD	1.036	0.164	Aug 2012	0.000		0.000		-		0.000	0.000	1.200	
MOVES System Reconfiguration	SS/FP	Thornhill Research, Inc:Toronto, Canada	1.000	0.677	Aug 2012	0.000		0.000		-		0.000	0.000	1.677	
Intranasal Carbon Dioxide for Headache	C/FFP	CAPNIA/McConnell Group:Rockville MD	0.250	0.000		1.130	Dec 2012	0.000		-		0.000	0.000	1.380	
USMC Resiliency Study II	SS/FP	HQ USMC:University of San Diego, CA	2.098	1.569	Jan 2012	2.400	Dec 2012	0.830	Dec 2013	-		0.830	Continuing	Continuing	Continuinç
USMC Suicide Prevention Program - Marine Resiliency Study	SS/FP	HQ USMC:VA San Diego, CA	0.702	0.561	Apr 2012	0.510	Dec 2012	0.000		-		0.000	0.000	1.773	
Individualized Fatigue- Based Scheduling and Countermeasure System	SS/FP	Pulsar Informatics:Philadelphia PA		1.348	Feb 2012	1.364	Dec 2012	0.000		-		0.000	0.000	4.060	
Sterilucent Sterilizer	C/FP	MARCORSYSCOM:Qu VA	antico 0.500	0.075	Sep 2012	0.000		0.000		-		0.000	0.000	0.575	
Intranasal Scopolamine for the Prevention of Motion Sickness in Dynamic Military Environments	Allot	NAMRU- Dayton:Dayton, OH	0.250	0.395	Aug 2012	0.125	Dec 2012	0.000		-		0.000	0.000	0.770	
Malaria Vaccine/Clinical Testing Amendment: Radiation-Attenuated Whole	Allot	NMRC:Silver Spring, MD	0.700	0.000		0.189	Dec 2012	0.246	Dec 2013	-		0.246	0.000	1.135	

PE 0604771N: Medical Development

UNCLASSIFIED Page 11 of 22

R-1 Line #125

Navy

Exhibit R-3, RDT&E Project Cost Analysis: PB 2014 Navy

R-1 ITEM NOMENCLATURE

PROJECT

APPROPRIATION/BUDGET ACTIVITY

0933: Medical/Dental Equipment Dev

FY 2014

Total

DATE: April 2013

1319: Research, Development, Test & Evaluation, Navy PE 0604771N: Medical Development BA 5: System Development & Demonstration (SDD) FY 2014 FY 2014 **Product Development (\$ in Millions)** oco FY 2012 FY 2013 Base Contract Method Performing All Prior Award Award Award **Cost Category Item** & Type Activity & Location Years Cost Date Date Cost Date Cost Cost

Target Award **Cost To** Total Value of Date Complete Cost Contract Cost Noise Induced Hearing Otologic, Loss: Administration of SS/FP Pharma:Carlsbad. 0.000 0.689 Aug 2012 0.000 0.000 0.000 0.689 0.000 NAC and HPN-07-Clinical Trials Case Western Synthetic Platelets in 0.162 Aug 2012 SS/FP University:Cleveland. 0.000 0.000 0.000 0.000 0.000 0 162 Swine Liver Injury Model OH **Battalion Aid Station** NHRC:San Diego, Allot 0.000 0.495 May 2012 0.000 0.000 0.000 0.000 0.495 Capabilities Study Biosurveillance Information NAMRU-2:Pearl Allot 0.000 0.381 Sep 2012 0.125 Dec 2012 0.150 Jun 2014 0.150 0.000 0.656 Service (BioServ) Harbor HI Implentation of an Alternative Watchstanding Naval Postgraduate MIPR 0.000 0.000 0.112 Dec 2012 0.000 0.000 0.000 0.112 Schedule on USN Surface School:Monterey, CA Combatants **Human Factors Support** NSMRL:Groton, CT 0.000 0.195 Aug 2012 0.215 Dec 2012 0.000 Allot 0.000 0.000 0.410 and Test of OWL Tool TML+ Scenario Run/Fleet NHRC:San Diego. **MIPR** 0.000 0.500 0.500 Jul 2012 0.000 0.000 0.000 0.000 Forces Plasma-Dry Blood NMRDC:Ft. Detrick. **MIPR** 0.150 0.000 0.000 0.000 0.000 0.000 0.150 Products-AFRIMS MD Field Friendly Rapid Blood NAMRU-SA:San Typing Capabilities to 0.000 0.240 Aug 2012 0.400 Dec 2012 0.385 Dec 2013 1 025 Allot 0.385 0.000 Antonio, TX Support Role II Units Validation of Computerized NAMRU-Color Vision Tests for Use 0.425 0.375 Dec 2012 0.000 Allot 0.000 Jul 2012 0.000 0.000 0.800 Dayton: Dayton, OH in Naval Aviation 3.949 Dec 2012 **Product Development TBD** Various:Not Specific 0.000 0.000 7.847 Dec 2013 7.847 0.000 11.796 Medical/Dental Equipment Allot Various:Not Specific 0.300 1.950 Sep 2012 2.173 Dec 2012 0.000 0.000 0.000 4.423 Development Test of Specialized Allot NSMRL:Groton, CT 0.000 0.000 0.010 0.010 Aug 2012 0.000 0.000 0.000 Lighting to Improve

PE 0604771N: Medical Development

Navy

UNCLASSIFIED

Page 12 of 22

Exhibit R-3, RDT&E Project Cost Analysis: PB 2014 Navy

R-1 ITEM NOMENCLATURE

DATE: April 2013
PROJECT

APPROPRIATION/BUDGET ACTIVITY

1319: Research, Development, Test & Evaluation, Navy BA 5: System Development & Demonstration (SDD)

PE 0604771N: Medical Development

0933: Medical/Dental Equipment Dev

Product Developmer	oduct Development (\$ in Millions)			FY 2	2012	FY 2	013	FY 2 Ba		FY 2		FY 2014 Total			
Cost Category Item Submariner Circadian Physiology	Contract Method & Type	Performing Activity & Location	All Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Program Suport	C/FFP	NMRC:Silver Spring, MD	0.200	0.181	Sep 2012	0.000		0.000		-		0.000	0.000	0.381	
Evaluation of an Alternative Watchstanding Schedule fo the US Navy Surface Warfare Community	Allot	NSMRL:Groton, CT	0.000	0.227	Aug 2012	0.000		0.000		-		0.000	0.000	0.227	
		Subtotal	9.234	14.018		14.880		9.458		0.000		9.458			
			All Prior					FY 2	2014	FY 2	2014	FY 2014	Cost To	Total	Target Value of

	All Prior Years	FY 2	2012	FY 2	2013	FY 2 Ba		FY 2014 Total	Cost To	Total Cost	Target Value of Contract
Project Cost Totals	9.234	14.018		14.880		9.458	0.000	9.458			

Remarks

PE 0604771N: *Medical Development* Navy

Page 13 of 22

Exhibit R-4, RDT&E Schedule Profile: PB 2014 Navy


APPROPRIATION/BUDGET ACTIVITY

1319: Research, Development, Test & Evaluation, Navy BA 5: System Development & Demonstration (SDD)

R-1 ITEM NOMENCLATURE PROJECT

PE 0604771N: Medical Development

0933: Medical/Dental Equipment Dev



2014DON - 0604771N - 0933

Exhibit R-4, RDT&E Schedule Profile: PB 2014 Navy

DATE: April 2013

APPROPRIATION/BUDGET ACTIVITY

1319: Research, Development, Test & Evaluation, Navy BA 5: System Development & Demonstration (SDD)

R-1 ITEM NOMENCLATURE

PE 0604771N: Medical Development

PROJECT

0933: Medical/Dental Equipment Dev

			•																									
MIGRAINES		FY 2012			FY	201	3		FY:	2014	ı		FY 2	2015	i		FY 2	2016			FY:	2017			FY	2018		
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Complete IRB Process				Milestone																								
Complete Enrollment of 400 Subjects with Migraine at MTFs and VA facilities					м	ilesto	ine																					
Analyze Data and Submit Findings to FDA								Milestone																				
FDA Review and Follow-On								Milestone																				

2014DON - 0604771N - 0933

Navy

UNCLASSIFIED Exhibit R-4, RDT&E Schedule Profile: PB 2014 Navy DATE: April 2013 APPROPRIATION/BUDGET ACTIVITY R-1 ITEM NOMENCLATURE **PROJECT** 1319: Research, Development, Test & Evaluation, Navy PE 0604771N: Medical Development 0933: Medical/Dental Equipment Dev BA 5: System Development & Demonstration (SDD) USMC SUICIDE FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 1Q 2Q 3Q 1Q 2Q 3Q 10 20 30 40 10 20 30 40 4Q 10 20 30 40 10 20 30 40 4Q 1Q 2Q 3Q 4Q psycological Autopsy Study- Full Milestone Report with Conclusions and Risk Checklist Impact of USMC Suicide on Family Milestone Survivors- Recommendations for Postvention Efforts Milestone Marine Resiliency 2014DON - 0604771N - 0933

UNCLASSIFIED Exhibit R-4, RDT&E Schedule Profile: PB 2014 Navy DATE: April 2013 APPROPRIATION/BUDGET ACTIVITY R-1 ITEM NOMENCLATURE **PROJECT** 1319: Research, Development, Test & Evaluation, Navy PE 0604771N: Medical Development 0933: Medical/Dental Equipment Dev BA 5: System Development & Demonstration (SDD) FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 INDIVIDUALIZED FATIGUE 1Q 2Q 3Q 4Q Milestone Develop Sub Community Schedule Milestone Test Schedule 2014DON - 0604771N - 0933

PE 0604771N: *Medical Development* Navy

Page 17 of 22

hibit R-4, RDT&E Schedule Prof	ile:	PB 2	2014	Nav	у																		D	ATE	: Apr	il 20	13	
PROPRIATION/BUDGET ACTIVI 19: Research, Development, Test 5: System Development & Demon	& <i>E</i> v				/y							E M N 0477						nent				JEC 3: Me		I/De	ntal	Equi	omei	nt De
orce Health Protection ransition Projects		FY 2	2012			FY	2013			FY 2	014			FY 2	015			FY 2	016			FY 2	2017			FY 2	2018	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Continue Development								Miles	stone																			
14DON - 0604771N - 0933	l							١																				

PE 0604771N: *Medical Development* Navy

UNCLASSIFIED
Page 18 of 22

Exhibit R-4A, RDT&E Schedule Details: PB 2014 Navy

APPROPRIATION/BUDGET ACTIVITY R-1 ITEM NOMENCLATURE PROJECT

1319: Research, Development, Test & Evaluation, Navy

PE 0604771N: Medical Development

0933: Medical/Dental Equipment Dev

BA 5: System Development & Demonstration (SDD)

0955. Medical/Derital Equipment Dev

Schedule Details

	Sta	art	Er	nd
Events by Sub Project	Quarter	Year	Quarter	Year
MALARIA				
Malaria Vaccine Research:	1	2012	4	2012
Adenovector Manufacturing:	1	2012	4	2012
Pre-Investigational New Drug and Toxicoligical Study:	1	2013	1	2013
Preparation of Materials for trials:	1	2013	1	2013
Clinical Trial: Schedule Detail	2	2013	4	2013
MIGRAINES				
Complete IRB Process:	4	2012	4	2012
Complete Enrollment of 400 Subjects with Migraine at MTFs and VA facilities: Schedule Detail	1	2013	3	2013
Analyze Data and Submit Findings to FDA: Schedule Detail	4	2013	4	2013
FDA Review and Follow-On: Schedule Detail	4	2013	4	2013
USMC SUICIDE			,	
psycological Autopsy Study- Full Report with Conclusions and Risk Checklist: Schedule Detail	1	2012	4	2012
Impact of USMC Suicide on Family Survivors- Recommendations for Postvention Efforts: Schedule Detail	1	2013	4	2013
Marine Resiliency: Schedule Detail	1	2014	4	2014
INDIVIDUALIZED FATIGUE				
Develop Sub Community Schedule: Schedule Detail	1	2012	4	2012
Test Schedule: Schedule Detail	1	2013	4	2013
Force Health Protection Transition Projects				
Continue Development: Schedule Detail	4	2013	1	2014

Exhibit R-2A, RDT&E Project Justification: PB 2014 Navy

DATE: April 2013

APPROPRIATION/BUDGET ACTIVITY R-1 ITEM NOMENCLATURE PROJECT

1319: Research, Development, Test & Evaluation, Navy PE 0604771N: Medical Development 9999: Congressional Adds

BA 5: System Development & Demonstration (SDD)

		()										
COST (\$ in Millions)	All Prior Years	FY 2012	FY 2013 [#]	FY 2014 Base	FY 2014 OCO ##	FY 2014 Total	FY 2015	FY 2016	FY 2017	FY 2018	Cost To Complete	Total Cost
9999: Congressional Adds	16.714	18.100	0.000	0.000	-	0.000	0.000	0.000	0.000	0.000	0.000	34.814
Quantity of RDT&E Articles	0	0	0	0		0	0	0	0	0		

^{*}FY 2013 Program is from the FY 2013 President's Budget, submitted February 2012

A. Mission Description and Budget Item Justification

Congressional Adds

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2012	FY 2013
Congressional Add: Military Dental Research	5.100	-
FY 2012 Accomplishments: All Navy Military Dental Research projects are underway. FY12 research efforts include a number of continuation projects from FY11. These efforts include the following accomplishments: Evaluation of Incidence and Treatment of Dental Emergencies in Deployed Personnel; Third Molar Related Dental Emergency and Extractions in Deployed Personnel; Design /Fabrication of Rapid Prototype Titanium Implement for Head /Neck Reconstruction.		
Congressional Add: Wound Care Research (transferred from Defense Health Program)	13.000	-
FY 2012 Accomplishments: The Wound Care Research Program is a comprehensive effort which continues to develop novel diagnostics and treatments to enhance the care of the wounded warfighter. The program utilizes cutting edge molecular assays and advanced computational biology to develop a device to predict the outcome of wounds. The development of novel treatments for wounds is based on the use of cells and factors to improve wound healing.		
Congressional Adds Subtotals	18.100	0.000

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

N/A

PE 0604771N: *Medical Development* Navy

Page 20 of 22

^{##} The FY 2014 OCO Request will be submitted at a later date

Exhibit R-2A, RDT&E Project Justification: PB 2014 Navy		DATE: April 2013
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: System Development & Demonstration (SDD)	R-1 ITEM NOMENCLATURE PE 0604771N: Medical Development	PROJECT 9999: Congressional Adds
E. Performance Metrics		
Not required for Congressional adds.		

Exhibit R-3, RDT&E Project Cost Analysis: PB 2014 Navy

DATE: April 2013

APPROPRIATION/BUDGET ACTIVITY

1319: Research, Development, Test & Evaluation, Navy BA 5: System Development & Demonstration (SDD)

PE 0604771N: Medical Development

R-1 ITEM NOMENCLATURE

PROJECT

9999: Congressional Adds

Test and Evaluation	st and Evaluation (\$ in Millions)				2012	FY 2	2013	FY 2 Ba	2014 Ise	FY 2		FY 2014 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	All Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To	Total Cost	Target Value of Contract
Congressional Add	C/BA Not Specified:Not Specified		16.714	18.100	Jan 2012	0.000		0.000		-		0.000	0.000	34.814	
	Subtotal					0.000		0.000		0.000		0.000	0.000	34.814	
		All Prior Years	FY:	2012	FY 2	2013	FY 2 Ba	2014 Ise	FY 2		FY 2014 Total	Cost To	Total Cost	Target Value of Contract	
Project Cost Totals			16.714	18.100		0.000		0.000		0.000		0.000	0.000	34.814	

Remarks

PE 0604771N: Medical Development Navy

Page 22 of 22